CANCER-ASSOCIATED RETINOPATHY

癌症相关视网膜病变

基本信息

项目摘要

Cancer Associated Retinopathies (CAR) occur most commonly in patients with small cell carcinoma of the lung (SCCL), although this phenomenon has also been encountered in patients with retinopathies associated with breast, colon, prostate and cervical carcinomas. CAR degenerations progress rapidly and are reported to manifest prior to the recognition of the causal cancer. Serum samples obtained from CAR patients have consistently demonstrated a specific antibody reaction with a 23 kDa retina protein which is now referred to as the retinal CAR antigen. The cloning of the cDNA corresponding to this antigen and its recognition as the photoreceptor molecule 'Recoverin' has identified an important link in the biological processes involved in these retinopathies. The molecular cloning of a cDNA of the same nucleic acid sequence from a cDNA library prepared from mRNA derived from a culture of SCCL identifies an immunological 'Cancer Connection' which could be responsible for initiating an autoimmune retinopathy. These finding introduce the hypothesis that, in some cancer associated retinopathies, 'Molecular Mimicry' is the cause of the collective indications of retinal hypersensitivity. The long term goals of this proposal are to investigate the pathogenesis of CAR. To ascertain the significance of the 23 kDa retinal CAR antigen/antibody reaction to vision loss in CAR patients and determine if this immunological response is directly involved in the retinopathic events that occur in CAR or is it simply a marker which identifies the presence of a SCCL aberrantly expressing a distinctive retinal protein. The specific aims are to (a) evaluate the incidence of expression of the retinal CAR antigen in cultures of SCCL deposited in the ATCC as well as in primary cultures of SCCL originated from CAR patients, (b) investigate the immunological response of experimental animals to sensitization to the potentially uveitogenic retinal CAR antigen and specific peptide components of the molecule and (c) characterize the nature of the genes expressing the retinal CAR antigen and the corresponding antigenic component identified in the culture of small cell carcinoma of the lung. The study will use a combination of immunological and molecular biology techniques to determine if the indications of retinal hypersensitivity associated with CAR represent an example of immune-mediated vision loss resulting from antigenic cross-reactions.
癌症相关的视网膜病(CAR)最常见于患者 尽管这种现象 与视网膜病变有关的患者也遇到了 乳房,结肠,前列腺和宫颈癌。 汽车退化 迅速进展,据报道在认识之前表现出来 因果癌。 从汽车患者获得的血清样品具有 始终证明与23 kDa的特异性抗体反应 视网膜蛋白现在称为视网膜抗原。 这 与该抗原相对应的cDNA的克隆及其识别为 感光细胞分子“恢复蛋白”已经确定了一个重要的链接 在这些视网膜病中涉及的生物过程中。 这 来自cDNA的相同核酸序列的cDNA的分子克隆 从源自SCCL培养的mRNA制备的库可以识别 免疫“癌症连接”,可能是负责的 发起自身免疫性视网膜病。 这些发现介绍了 假设在某些癌症相关的视网膜病中,分子 模仿是视网膜集体指示的原因 高敏性。 该提案的长期目标是研究发病机理 汽车。 确定23 kDa视网膜汽车的重要性 汽车患者对视力丧失的抗原/抗体反应,并确定是否是否 这种免疫反应直接参与视网膜病 汽车中发生的事件,或者仅仅是标记的标记 SCCL的存在异常表达独特的视网膜蛋白。 具体目的是(a)评估表达的发生率 SCCL培养物的视网膜抗原以及ATCC中的SCCL培养基 在SCCL的原发性培养物中起源于汽车患者,(b)研究 实验动物对敏化对敏化的免疫学反应 潜在的葡萄膜源性视网膜抗原和特异性肽 分子的成分和(c)表征了基因的性质 表达视网膜抗原和相应的抗原 在肺的小细胞癌中鉴定出的成分。 该研究将结合免疫学和分子生物学 确定视网膜超敏反应的指征的技术 与汽车相关的是免疫介导的视力丧失的例子 由抗原交叉反应产生。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

CHARLES Edward THI...的其他基金

CANCER-ASSOCIATED RETINOPATHY
癌症相关视网膜病变
  • 批准号:
    2162674
    2162674
  • 财政年份:
    1993
  • 资助金额:
    $ 18.74万
    $ 18.74万
  • 项目类别:
CANCER-ASSOCIATED RETINOPATHY
癌症相关视网膜病变
  • 批准号:
    2162672
    2162672
  • 财政年份:
    1993
  • 资助金额:
    $ 18.74万
    $ 18.74万
  • 项目类别:
EXPERIMENTAL ARTHRITIS ASSOCIATED ANTERIOR UVEITIS
实验性关节炎相关的前葡萄膜炎
  • 批准号:
    3260463
    3260463
  • 财政年份:
    1984
  • 资助金额:
    $ 18.74万
    $ 18.74万
  • 项目类别:
EXPERIMENTAL ARTHRITIS ASSOCIATED ANTERIOR UVEITIS
实验性关节炎相关的前葡萄膜炎
  • 批准号:
    3260462
    3260462
  • 财政年份:
    1984
  • 资助金额:
    $ 18.74万
    $ 18.74万
  • 项目类别:
EXPERIMENTAL ARTHRITIS ASSOCIATED ANTERIOR UVEITIS
实验性关节炎相关的前葡萄膜炎
  • 批准号:
    3260464
    3260464
  • 财政年份:
    1984
  • 资助金额:
    $ 18.74万
    $ 18.74万
  • 项目类别:

相似海外基金

Regulators of Immune Complex Mediated Neutrophil Recruitment and Tissue Injury
免疫复合物介导的中性粒细胞募集和组织损伤的调节因子
  • 批准号:
    10063998
    10063998
  • 财政年份:
    1999
  • 资助金额:
    $ 18.74万
    $ 18.74万
  • 项目类别:
AUTOIMMUNE THROMBOCYTOPENIA
自身免疫性血小板减少症
  • 批准号:
    6184649
    6184649
  • 财政年份:
    1998
  • 资助金额:
    $ 18.74万
    $ 18.74万
  • 项目类别:
AUTOIMMUNE THROMBOCYTOPENIA
自身免疫性血小板减少症
  • 批准号:
    6527511
    6527511
  • 财政年份:
    1998
  • 资助金额:
    $ 18.74万
    $ 18.74万
  • 项目类别:
AUTOIMMUNE THROMBOCYTOPENIA
自身免疫性血小板减少症
  • 批准号:
    2750668
    2750668
  • 财政年份:
    1998
  • 资助金额:
    $ 18.74万
    $ 18.74万
  • 项目类别:
AUTOIMMUNE THROMBOCYTOPENIA
自身免疫性血小板减少症
  • 批准号:
    6390178
    6390178
  • 财政年份:
    1998
  • 资助金额:
    $ 18.74万
    $ 18.74万
  • 项目类别: